On Monday, Henry Schein received an upgrade to its Relative Strength (RS) Rating, from 69 to 74.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating north of 80 as they launch their largest climbs. See if Henry Schein can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
While Henry Schein is not near a proper buying range right now, see if it is able to form and break out from a proper consolidation.
Henry Schein saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -8% to 80%. Revenue rose from 0% to 6%.
Henry Schein holds the No. 1 rank among its peers in the Medical-Supplies industry group. Henry Schein and Patterson Cos are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
